EpiBiologics
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
1900 Alameda De Las Pulgas 250, San Mate...Website
www.epibiologics.comRevenue
$11 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
2
1
2
1
1
About EpiBiologics
EpiBiologics is advancing a next-generation protein degradation pipeline and platform that targets extracellular membrane and soluble proteins. EpiBiologics was founded on pioneering work from scientific founder Dr. Jim Wells of the University of California, San Francisco (UCSF). The Companys proprietary EpiTAC platform is a modular bispecific antibody system that enables targeted degradation of disease-driving extracellular proteins in a tissue-specific manner. EpiBiologics is backed by leading healthcare investors and aims to develop first-in-class and best-in-class targeted therapies across multiple therapeutic areas, including oncology and immunology.Explore more
EpiBiologics Org Chart
Get the full picture
Sign in to uncover key details.
Get the full picture
Sign in to uncover key details.
Show More
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is EpiBiologics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on EpiBiologics recently announced quarterly report
Check if EpiBiologics has recently received funding, and reach out quickly before it becomes old news!
EpiBiologics, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when EpiBiologics launches new products
Funding: Get notified immidiatlly once EpiBiologics has new funding data
Check out if EpiBiologics is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at EpiBiologics
Click to see if EpiBiologics had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at EpiBiologics
Find 2 more new buyers
Compare Similar Companies to EpiBiologics
Compare insights from companies similar to EpiBiologics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
EpiBiologics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
EpiBiologics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about EpiBiologics.
EpiBiologics financials insights
Gather financial insights about EpiBiologics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2023
Series A
$50M
2026
Series B
$107M
EpiBiologics Tech Stack
A closer look at the technologies used by EpiBiologics
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Funding
Funding
Event
Events, Engineering, Research & Development, Training, Machine Learning, Learning & Development, Search, Laboratory Operations, Medical Education & Training, Medical Research, Chemical Engineering, Artificial Intelligence, Clinical Operations, Healthcare Technology, HR Operations, Operations
Event
Events
New Hire
Executive Move
EpiBiologics News & Media
EpiBiologics raises $107M for its protein-degrading cancer drug | BioPharma Dive
The startup is developing a medicine that can very specifically degrade cancerous forms of EGFR, the target of an array of marketed therapies.EpiBiologics Presents First Data on c-Met Degrading Bispecific Antibody
SAN MATEO, Calif.--(BUSINESS WIRE)--EpiBiologics, a leader in tissue-selective extracellular protein degradation, today presented the first preclinical data on its EpiTAC bispecific antibody degrader of c-Met, a potential first-in-class therapy for a range of cancers driven by mutated, amplified, or overexpressed c-Met signaling. The data, which were presented in a poster at the American Association for Cancer Research (AACR) Annual Meeting, show that c-Met degrading EpiTACs demonstrate strongEpiBiologics to Present Data Demonstrating Disease-Selective Extracellular Protein Degradation and Platform Breadth at Upcoming Scientific Meetings
SAN MATEO, Calif.--(BUSINESS WIRE)--EpiBiologics, a leader in tissue-selective extracellular protein degradation, will be presenting new data demonstrating the unique capabilities of its EpiTAC platform at the 16th Annual PEGS Europe conference (November 5-7, 2024 in Barcelona, Spain) and the 2024 Antibody Engineering and Therapeutics US conference (December 15-18, 2024 in San Diego, California). “We’re pleased to present in vivo data demonstrating significant platform validation and the potentEpiBiologics Extracellular Protein Degraders Demonstrate Robust Preclinical Anti-tumor Activity and Survival Benefit
SAN MATEO, Calif.--(BUSINESS WIRE)-- #AACR--EpiBiologics Extracellular Protein Degraders Demonstrate Robust Preclinical Anti-tumor Activity and Survival Benefit at AACR
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding EpiBiologics
Sign Up For FreeTo access detailed company insights
EpiBiologics is advancing a next-generation protein degradation pipeline and platform that targets extracellular membrane and soluble proteins. EpiBiologics was founded on pioneering work from scientific founder Dr. Jim Wells of the University of California, San Francisco (UCSF). The Companys proprietary EpiTAC platform is a modular bispecific anti... Read More
